COMMUNIQUÉS West-GlobeNewswire

HealthEquity Assist™: A new suite of integrated benefit solutions that drive deeper engagement, deliver cost savings, and increase transparency for employee benefits
18/03/2025
Set of seamlessly integrated tools to help employers drive cost savings, simplify spending decisions, and engage their employees DRAPER, Utah, March 18, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (Nasdaq: HQY) (" [...]
GRI Bio Participates in a Virtual Investor CEO Connect Segment
18/03/2025
Access the CEO Connect segment here LA JOLLA, CA, March 18, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T [...]
Celebrating a Decade of Care: Aeroflow Urology Marks 10 Years of Supporting Those Afflicted by Incontinence Across the U.S.A.
18/03/2025
Aeroflow Urology's 97% customer satisfaction rating is a testament to the company’s commitment to personalized care and improving access to critical care supplies ASHEVILLE, N.C., March 18, 2025 (GLOBE NEWSWIRE) -- This [...]
NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace
18/03/2025
EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and [...]
Leading Academic and Manufacturing Organizations Join Ori Biotech’s Preferred Partner Network to Accelerate the Commercialization of Cell and Gene Therapies
18/03/2025
Preferred Partner Network (PPN) members will become Centers of Excellence for the IRO ® platform combining best-in-class technology with industry-leading development and manufacturing capabilities. PHILADELPHIA and [...]
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
18/03/2025
-- Company taps first EU distributors, Comercial Medico Quirurigca, SA and Durgalab, as the first globally to be granted rights to commercialize FemBloc ® -- ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., ( [...]
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
18/03/2025
SAN MATEO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has entered into a non-binding letter of intent (“LOI”) with Global Digital Holdings Inc., conducting [...]
Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain
18/03/2025
Opioid-free and addiction-free pain treatment therapy could address $1.5B worldwide CINP market ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a [...]
Outset Medical Announces One-for-Fifteen Reverse Stock Split
18/03/2025
SAN JOSE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and [...]
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
18/03/2025
WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat [...]
March 2025 Letter to Shareholders
18/03/2025
VANCOUVER, Washington, March 18, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As envisioned, 2025 is unfolding to be an exciting year for CytoDyn Inc. (“CytoDyn” or the “Company”). On February 24, 2025, the Company [...]
CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025
18/03/2025
BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and [...]
New InStride Health Data Reveals Overall Clinical Improvement in 98% of Youth with Anxiety and/or OCD
18/03/2025
Second Annual Outcomes Report confirms comprehensive, evidenced-based treatment program continues to prove clinically meaningful for graduates and families BOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- InStride Health, an [...]
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
18/03/2025
HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer [...]
Prenetics’ IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market
18/03/2025
Adds Renowned Clinical Experts Dr. Jeremy London and Dr. Amy Shah to Existing Team from Mayo Clinic, Cedars-Sinai, NASA and Yale University CHARLOTTE, N.C., March 18, 2025 (GLOBE NEWSWIRE) -- IM8 , the premium [...]
Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient
18/03/2025
Ramat Gan, Israel, March 18, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological [...]
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
18/03/2025
HYDERABAD, India and REYKJAVIK, Iceland, March 18, 2025 (GLOBE NEWSWIRE) -- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr [...]
AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test
18/03/2025
AccuStem pursuing strategic commercialization plan intending to launch the MSC test in the US in 2026 LONDON and PHOENIX, Ariz., March 18, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage [...]
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
18/03/2025
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”) and Alvotech (NASDAQ: ALVO), a global biotech company [...]

Pages